← Leaderboards
Debra Kimless
Pure Green Pharmaceuticals, Inc.
$683,775
Attributed
$2,051,325
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$2,051,325 · 1
By mechanism
R44$2,051,325 · 1
Top collaborators
- Salahadin Abdi2 shared
- Mark S Wallace2 shared
Others in their field
Other Rising Stars on “Addiction Liability”
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Glenn Short III · Atai Therapeutics, Inc.$2,923,842
- Brittney L Keller-Hamilton · Ohio State University$2,590,564
- Ruth Huttenhain · University Of California, San Francisco$2,364,012
- Joseph Grieco · Park Therapeutics, Inc.$2,218,061
- Ahmad El Hellani · American University Of Beirut$2,153,195
Research focus
Addiction LiabilityChronicAdverse EventAdverse ReactionsAbsorptionAffectAlternative TherapiesAmputationAnalgesicsAnticonvulsantsAdvocateAdverse EffectsAnti-Inflammatory AgentsAntioxidantsAnxietyAnxiety ReductionBeta-CyclodextrinsBiological AvailabilityBypassCaliforniaCannabidiolCase Report FormCategoriesClinical Data
Grant awards (2)
Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy$932,613
R44 · FY2024 · DK · contact PI
Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy$1,118,712
R44 · FY2023 · DK · contact PI